New drug cocktail aims to boost stem cell transplant success in rare lymphoma
NCT ID NCT07276737
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This study tests whether a combination of three chemotherapy drugs (thiotepa, cyclophosphamide, and busulfan) given before a stem cell transplant can help people with NK/T-cell lymphoma live longer without their cancer coming back. About 37 adults aged 18 to 70 who are in remission will take part. The approach aims to prepare the body for the transplant and control the disease, but ongoing monitoring and possible long-term medication are still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NK/T-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.